Vnitr Lek 2024, 70(2):108-112 | DOI: 10.36290/vnl.2024.022
Resistant hypertension
- II. interní klinika LF UK a FN Plzeň
Resistant hypertension is defined as blood pressure (BP) ≥ 140/90 mmHg despite administration of at least three antihypertensive drugs including diuretics in maximum tolerated doses. Pseudoresistance due to bad adherence to treatment is very common. Ambulatory BP monitoring should be done should be performed as up to one third of patients has ambulatory BP within normal limits. Secondary causes of hypertension should be excluded. Resistance on treatment is common in patients with renal parenchymatous hypertension. The diagnosis of primary aldosteronism may be more difficult and may occur also in young patients with hypertension. Other causes include diabetes mellitus with advanced organ complications or advanced general atherosclerosis. Response to treatment may also be suppressed by some drugs. Diuretics are very important in the treatment of resistant hypertension because volume expansion, sometimes inapparent, is common. Chlortalidone and indapamide are preferred. Spironolactone can be added as a fourth drug; in individuals with a risk of hyperkalaemia, betablocker or alphablocker should be used. Denervation of renal sympathicus has not been proved to be more effective than drug therapy.
Keywords: resistant hypertension, pseudoresistance, adherence to treatment, secondary hypertension, response to treatment.
Accepted: March 26, 2024; Published: April 10, 2024 Show citation
References
- Mancia G, Kreutz R, et al. 2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023.
- Widimský J, Filipovský J, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze. Doporučení České společnosti pro hypertenzi. Hypertenze a KV prevence. 2022;2:1-25. Available from: www.hypertension.cz.
- Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385:2507-19.
Go to original source...
Go to PubMed...
- Williams B, MacDonald TM, Morant S et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-68.
Go to original source...
Go to PubMed...
- Tsujimoto T, Kajio H. Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension. J Am Heart Assoc. 2020;9:e018827.
Go to original source...
Go to PubMed...
- Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005;46:481-487.
Go to original source...
Go to PubMed...
- Kario K, Ferdinand KC, Vongpatanasin W. Are SGLT2 inhibitors new hypertension drugs? Circulation. 2021;143:1750-1753.
Go to original source...
Go to PubMed...
- Ribeiro-Silva JC, Tavares CAM, Girardi ACC. The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms. Current Opinion in Pharmacology Volume 69, April 2023;69:102355.
Go to original source...
Go to PubMed...
- Williams B, Cockroft JR, Kario K, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension. The PARAMETER Study. Hypertension. 2017;69:411-42. trial
Go to original source...
Go to PubMed...
- Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400:1927-1937.
Go to original source...
Go to PubMed...